stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) EPS (diluted)
Novo Nordisk A/S's EPS (diluted) for fiscal 2025 was $3.49, up 6.40% from $3.28 in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.09. Over the past ten years it has ranged from $1.01 (fiscal 2015) to $3.49 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 6 consecutive fiscal years. Novo Nordisk A/S ranks 8th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $3.49 | 6.40% |
| FY2024 | $3.28 | 21.48% |
| FY2023 | $2.70 | 56.07% |
| FY2022 | $1.73 | 4.85% |
| FY2021 | $1.65 | 19.57% |
| FY2020 | $1.38 | 12.20% |
| FY2019 | $1.23 | (2.38%) |
| FY2018 | $1.26 | 7.69% |
| FY2017 | $1.17 | 9.35% |
| FY2016 | $1.07 | 6.47% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.74 | (56.73%) |
| Mar 2026 | $1.71 | 81.91% |
| Dec 2025 | $0.94 | 34.29% |
| Sep 2025 | $0.70 | (23.08%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $17.24 |
| AZN AstraZeneca PLC compare | $7.06 |
| NVS Novartis AG compare | $5.24 |
| BMY Bristol Myers Squibb Company compare | $4.51 |
| NVO Novo Nordisk A/S | $4.09 |
| GSK GSK PLC Sponsored ADR compare | $2.98 |
| SNY Sanofi compare | $2.02 |
| PFE Pfizer Inc. compare | $0.71 |
| GILD Gilead Sciences, Inc. compare | −$3.16 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on NVO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement